While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants, Surgeons, and Biopsies Since Launch and Strong Early MACI Arthro Launch Indicators Record Fourth Quarter Gross Margin of Approximately 77% and Adjusted EBITDA Margin of 39% 2025 Total Revenue Guidance of 20% to 23% Growth Mid-Term Profitability Targets Increased to Gross Margin in the High- ...

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Ver ...

We are currently offering a one-month trial into the Biotech Forum at half the regular price. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just join our community at The Biotech Forum by clicking HERE .Today, we take a deeper peak at Vericel Corporation (NASDAQ: VCEL ) whose stock has moved up some 40% in recent months. The company is moving to profitably this fiscal year and is seeing impressive sales growth. That said, after the recent rise in equity, v ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Mike Kratky - Leerink Partners Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Ladies and gentlemen, thank you for standing ...

Financial Data and Key Metrics Changes - The company reported total revenue growth of 27%, achieving approximately $58 million in record third-quarter revenue, exceeding guidance for the quarter [6][15] - Gross profit reached $41.7 million, representing 72% of net revenue, an increase of 480 basis points compared to the previous year [17] - Net loss narrowed to $0.9 million, or $0.02 per share, compared to $3.7 million, or $0.08 per share, in the prior year [18] - Adjusted EBITDA increased 84% to $10 million, or 17% of revenue, reflecting strong bottom-line growth [19] Business Line Data and Key Metrics Changes - MACI revenue grew 19% in the third quarter to $44.7 million, on track for approximately 20% growth for the full year [15][21] - Total Burn Care revenue grew 66% to $13.2 million, driven by record Epicel revenue of $12.2 million [15][16] - NexoBrid revenue increased sequentially to $1.1 million, with more burn centers adopting the product [16] Market Data and Key Metrics Changes - The company achieved record third-quarter highs for MACI biopsies and the number of surgeons taking biopsies, indicating robust growth in underlying growth drivers [9] - Over 70 burn centers completed P&T committee submissions for NexoBrid, with approximately 50 centers placing initial orders [11] Company Strategy and Development Direction - The company aims to sustain high revenue growth for MACI and establish a second high-growth franchise in burn care [12] - The recent FDA approval of MACI Arthro positions the company for sustained high revenue and profit growth [8] - The company plans to initiate the MACI Ankle development program and expects to submit an IND in the first half of 2025 [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of high top-line growth and significant margin expansion in 2024 [22] - The company anticipates durable growth in its core portfolio and expects MACI Arthro to significantly impact overall MACI utilization [26] - Management noted that the cash generation profile will improve significantly in 2025 and beyond as the company completes its new manufacturing facility [57] Other Important Information - The company maintained its total revenue guidance for the full year at $238 million to $242 million, implying fourth-quarter revenue of $76 million to $80 million [21] - The company ended the third quarter with $151 million in cash, restricted cash, and investments, and no debt [19] Q&A Session All Questions and Answers Question: Can you talk about the drivers for growth next year, particularly for NexoBrid? - Management indicated that while they are not providing specific guidance for 2025, they expect continued progression for NexoBrid and strong growth for MACI [31][34] Question: What are you seeing from the new 2,000 surgeons in terms of MACI Arthro? - Management noted that initial cases are coming from both existing MACI users and new surgeons, indicating strong early interest [40][42] Question: How do you see MACI Arthro impacting your overall growth? - Management expects MACI Arthro to provide a modest contribution to growth initially, with potential for greater impact as adoption increases [36][61] Question: Can you provide insights on MACI pricing and potential increases in 2025? - Management stated that they typically implement high single-digit price increases annually and expect to do so in 2025 [75] Question: How is the training for MACI Arthro procedures being conducted? - Management explained that training is primarily done online, with additional hands-on training available through cadaver labs [88][90]

Vericel Corporation (VCEL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.10, delivering no surprise.Over the last four quarters, the company has surpassed consen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35280 VERICEL CORPORATION (Exact name of registrant as specified in its charter) Michigan 94-3096597 (State or other jurisdiction of incorporation or organization) (I.R ...

▼VERICEL | --- | --- | --- | |-------------------------|-------|-------| | | | | | | | | | VERICEL Q3 2024 RESULTS | | | | NOVEMBER 7, 2024 | | | | --- | --- ...